Addex Therapeutics (ADXN)

• Market cap: $8.45M
• 1 day: -1.86%
• 5 days: -10.52%
• 1 month: -24.23%
• 3 months: 2.33%
• 6 months: -10.11%
• Year to date: 25.56%
• 1 year: 25.56%
• 5 years: -97.27%
• 10 years: -97.27%

About: Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Employees: 23

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more funds holding

Funds holding: 2 [Q2] → 3 (+1) [Q3]

0% less ownership

Funds ownership: 0% [Q2] → 0% (-0%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

58% less capital invested

Capital invested by funds: $32.1K [Q2] → $13.6K (-$18.5K) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30 279% upside
• Avg. target: $30 279% upside
• High target: $30 279% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 41% 1-year accuracy 126 / 309 met price target	279% upside $30	Buy Reiterated	2 Oct 2024
HC Wainwright & Co. Raghuram Selvaraju 41% 1-year accuracy 126 / 309 met price target	279% upside $30	Buy Reiterated	28 Aug 2024